國家衛生研究院 NHRI:Item 3990099045/12468
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 958320      線上人數 : 826
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/12468


    題名: Liver-related long-term outcomes of thiazolidinedione use in persons with type 2 diabetes
    作者: Yen, FS;Yang, YC;Hwu, CM;Wei, JC;Huang, YH;Hou, MC;Hsu, CC
    貢獻者: Institute of Population Health Sciences
    摘要: BACKGROUND & AIMS: Studies have described prominent histologic improvement in patients with nonalcoholic steatohepatitis (NASH) using thiazolidinedione (TZD); however, these were all short-term with moderate sample size, no liver-related long-term outcomes could be noted. METHODS: This retrospective cohort study enrolled patients with newly diagnosed type 2 diabetes mellitus (T2DM) from Taiwan's National Health Insurance Research Database between January 1, 2000, and December 31, 2013. We matched TZD users and nonusers at a 1:1 ratio through propensity score matching. This study included 5095 paired TZD users and nonusers. Cox proportional hazard models were used to compare the risks of liver cirrhosis, hepatic decompensation, hepatic failure, and all-cause mortality between TZD users and nonusers. The Kaplan-Meier method was used to compare the cumulative incidence of these main outcomes. RESULTS: The incidence rates of liver cirrhosis, hepatic decompensation, hepatic failure, and all-cause mortality during follow-up were 0.77 versus 1.95, 1.43 versus 1.75, 0.36 versus 0.70, and 4.89 versus 3.78 per 1000 person-years between TZD users and nonusers. The adjusted hazard ratios of liver cirrhosis, hepatic decompensation, hepatic failure, and all-cause mortality were 0.39 (95% confidence interval [CI]: 0.21-0.72), 0.86 (95% CI: 0.52-1.44), 0.46 (95% CI: 0.18-1.17), and 1.18 (95% CI: 0.87-1.61), respectively. CONCLUSIONS: Our study demonstrated that TZD use could significantly lower the risk of liver cirrhosis. In clinical settings, TZD use might be able to improve liver-related long-term outcomes.
    日期: 2020-05
    關聯: Liver International. 2020 May;40(5):1089-1097.
    Link to: http://dx.doi.org/10.1111/liv.14385
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1478-3223&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000512129200001
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85079445831
    顯示於類別:[許志成] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB31960563.pdf12920KbAdobe PDF320檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋